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Abstract
Venous thromboembolism is the third common vascular disease after acute myocardial 
infarction and stroke, and acute pulmonary embolism (PE) remains as the most common 
preventable cause of in-hospital mortality. In addition to routine anticoagulant therapy, 
several advanced treatment options have been introduced over the past three decades. 
We provide a succinct and contemporary summary of the evidence base and important 
indications for inferior vena caval filter placement, systemic and catheter-based 
thrombolytic therapy, as well as percutaneous and surgical thrombectomy. Appropriate 
case selection for advance therapies for PE could minimize the adverse effects and costs, 
while optimizing the outcomes.
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Acute pulmonary embolism (PE) is a common and poten-
tially lethal medical condition. Annually, there are an esti-
mated 1,000,000 cases of PE in the Western countries [1, 
2]. Thirty-day mortality rates have been variably reported 
between 6-9% in contemporary registries, and up to as high 
as 50% in patients with massive PE, defined by development 
of systemic hypotension [3-5]. Beyond systemic anticoag-
ulation, advanced treatment approaches have opened their 
way in several subgroups of patients with PE. Such options 
include inferior vena caval (IVC) filters, thrombolytic ther-
apy (with or without ultrasound facilitation), and surgical or 
percutaneous thrombectomy. Here, we provide a succinct re-
view of the latest evidence and recommendations relating to 
advanced treatments for acute PE.
IVC Filters
A recent analysis of Medicare beneficiaries > 65 years old 
demonstrated that roughly 17% of patients hospitalized 
with a PE, an unexpectedly high proportion, received an 
IVC filter [6]. Such findings are particularly striking taking 
into consideration the limited available evidence for effica-
cy of IVC filters.
So far, there have only been two major randomized con-
trolled trials published on the use of IVC filters [7, 8]. The 
PREPIC trial, an open-label study of 400 patients with 
proximal deep vein thrombosis (DVT) randomized to IVC 
filter placement plus anticoagulation versus anticoagulation 
alone did not show a mortality difference between the two 
groups at 2-year or 8-year follow-up, and the reduced rates 
of PE in the study were counterbalanced by increased rate 
of recurrent DVT [7-9]. With technological advances, such 
as introduction of retrievable filters (that would have po-
tentially mitigated the increased risk of recurrent DVT be-
low the filter), use of IVC filters continued to grow despite 
the dearth of clinical evidence for improved outcomes. In 
recent years, results of the PREPIC II trial, an open-label 
study of 400 patients hospitalized with acute symptomatic 
PE with concomitant lower extremity DVT and at least one 
feature increasing the risk of PE recurrence, who were ran-
domized to anticoagulation alone versus anticoagulation 
plus (retrievable) IVC filters, became available. At 3-month 
follow-up, the study did not detect a difference in mortal-
ity rates, and reported statistically similar but numerically 
higher rates of PE in patients who did receive an IVC fil-
ter [10]. Several other recent studies have also shown that 
many patients have received IVC filters in scenarios other 
than those recommended by the expert guidelines [11].
In summary, the overall existing evidence for the use of IVC 
filters is quite limited, and these devices should only be 
used as a last resort once there is no other evidence-based 
option available. Expert guidelines recommend against use 
of IVC filters as a routine treatment for acute PE. The lim-
ited reasonable indications for IVC filter placement would 
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include contraindication to anticoagulant therapy [12], 
and recurrent events despite adequate anticoagulation (i.e. 
recurrence despite anticoagulation with good adherence 
and objective evidence of therapeutic anticoagulant levels). 
There is no consensus for use of IVC filters in other scenar-
ios, such as presence of poor cardiopulmonary baseline re-
serve, or in the case of massive PE. 
Systemic Thrombolytic treatment
Along with the conceivable benefits of thrombolytic ther-
apy for an acute thrombotic condition such as PE comes 
the cost in the form of bleeding events, with the absolute 
risks increasing by increased age, including that of intracra-
nial hemorrhage, the most feared bleeding complication of 
thrombolytics. Appropriate use of thrombolysis is associ-
ated with more rapid resolution of symptoms, cardiorespi-
ratory (hemodynamic) stabilization, improvement in right 
ventricular function, improved exercise tolerance, preven-
tion of PE recurrence, and according to a recent system-
atic review of the literature (predominated driven by the 
PIETHO trial participants), improved survival [13-16].
Increased risk of bleeding is well known with thrombolytic 
therapy, especially among older adults. Yet, the benefits of 
thrombolytic therapy among older adults are frequently un-
derrated [17] while the risk of bleeding from thrombolysis 
in elderly PE patients is traditionally exaggerated; although 
this idea has been challenged in several recent studies [18-
20]. Nevertheless, several studies suggest that use of throm-
bolytic therapy is rare in older adults [18, 21].
Use of ultrasound-facilitated thrombolysis emerged as a fas-
cinating option in recent years, which was associated with 
an excellent safety profile in a small randomized trial and a 
prospective single arm study of patients with sub-massive 
or massive PE. The improved safety profile is likely due to 
lower dose of thrombolytics (up to a quarter of regular sys-
temic dose) and administration over 12-24 hours according 
to various protocols, as opposed to bolus administration of 
regular systemic thrombolytics [22, 23]. Reduced-dose sys-
temic thrombolytic therapy has been also successfully tried 
in a small study of patients with “moderate PE” (defined as 
computed tomographic pulmonary angiographic evidence 
of involvement of > 70% in ≥ 2 lobar or left or right main 
pulmonary arteries) [14].
Massive PE, i.e. PE along with hemodynamic instability, 
represents the clearest indication of thrombolytic therapy. 
Risks and benefits of thrombolytic therapy in patients with 
non-massive PE should be seriously considered (Fig 1). 
While reduced-dose thrombolysis could be reasonable in a 
select group of patients with sub-massive (or even moder-
ate) PE, routine use of thrombolytic therapy in all-comers 
with PE is not recommended.
Catheter Directed Treatments Other Than Throm-
bolytic Therapy
Catheter directed treatment may refer to any or a combina-
tion of catheter directed thrombectomy, catheter directed 
fragmentation and catheter directed thrombolysis. Cath-
eter-directed thrombolytic therapy could be performed 
alone, or in conjunction with thrombus aspiration using 
catheters such as the regular 8F guide catheters [24]. Sever-
al other percutaneous thrombectomy devices are also under 
early investigation, and at least one of them (the AngioVac 
Cannula) has received FDA approval for removal of detri-
mental intravascular material, such as soft thrombi [24].
Figure 1: Risks and Benefits of Thrombolytic Therapy in Patients 
with PE
Surgical Thrombectomy
Surgical embolectomy, a procedure that requires much ex-
pertise and is performed under cardiopulmonary bypass, 
occurs only in very experienced centers. In patients suffering 
from massive PE who have contraindications to, or are not 
good candidates for thrombolytic therapy, and have a reason-
able operative risk, surgical thrombectomy, with or without 
extracorporeal membrane oxygenation (ECMO) could be 
life-saving. However, because of the extreme level of illness 
of such patients, conducting high-quality prospective com-
parative effectiveness in such patients has not been yet feasi-
ble. Data from the US indicates a declining trend for utiliza-
tion rates of surgical thrombectomy, likely as a result of more 
widespread availability of other advanced therapies [21].
CONCLUSIONS
With new emerging evidence for more aggressive treatment 
of PE with potentials for decreased mortality and long-term 
morbidity, it appears that options for PE treatment will 
broader in future. Prior to choosing advanced therapies, 
however, risk stratification would be crucial. The concept 
of a pulmonary embolism response team (PERT) is now 
growing in several centers around the world and might help 
improve decision-making for the choice and timeliness of 
PE advanced therapies, where needed. With wise use of 
PERT teams, collaborative interdisciplinary efforts, and 
other initiatives to raise the awareness for optimal diagnosis 
and treatment of PE we can aim to reduce the burden of 
venous thromboembolism, one of the most common and 
yet underappreciated cardiovascular conditions.
Careful consideration of benefits and risks is key, particular-
ly for patients with hemodynamically-stable PE who have 
other features of increased risk of adverse events. Risks of 
hemorrhagic complications should be particularly weighed 
in the case of older adults. Reduced-dose thrombolytics are 
a fascinating option with a seemingly better safety profile 
and currently under intense investigation (Table 1).
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Table 1: Summary of Select Indications for Advanced Therapies for Acute PE
Therapies
Inferior Vena Caval (IVC) Filters
Acute PE with clear contraindications to anticoagulant therapy IVC filter placement is reasonable
Recurrent PE despite adequate anticoagulant therapy IVC filter placement is reasonable
 Acute PE with poor cardiopulmonary reserve, including massive
PE
IVC filter placement might be considered in select cases.
Acute hemodynamically-stable PE in patients tolerant of antico-
agulants
IVC filter placement is not recommended.
Thrombolytic Therapy
 Massive PE (hemodynamic instability not attributable to other
factors)
Thrombolytic therapy is recommended
 PE with elevated cardiac biomarkers and imaging evidence of
right ventricular dysfunction
Thrombolytic therapy (preferentially low-dose or ultra-
sound-facilitated) may be considered in select cases.
 Hemodynamically stable PE without evidence of biomarkers rise
and right ventricular dysfunction (all-comers with acute PE)
Thrombolytic therapy is not recommended.
Catheter Directed Therapies Other Than Thrombolysis
Acute severe PE (large burden, clot in-transit)  Catheter directed techniques (e.g. aspiration/ thrombectomy)
might be considered in experienced centers for select cases.
Surgical Thrombectomy
Acute massive PE and acceptable surgical risk  Surgical thrombectomy should be considered in cases of acute
massive PE in highly experienced centers.
Acute severe PE (large burden, clot in-transit)  Surgical thrombectomy might be considered in select cases of
large burden PE in highly experienced centers.
Acute hemodynamically-stable PE (all-comers with acute PE) Routine use of surgical thrombectomy is not recommended.
  Use of a multidisciplinary Pulmonary Embolism Response Team (PERT) can help facilitate the selection of advanced therapies in each
case.
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